Sernova Provides Corporate Update and Results of 2013 Annual General Meeting
(firmenpresse) - LONDON, ONTARIO -- (Marketwired) -- 05/09/13 -- Sernova Corp. (TSX VENTURE: SVA), provides a corporate update on the clinical development of the Cell Pouch™ and projections for 2013. As well, it is pleased to announce the results of the 2013 Annual General Meeting (AGM).
Cell Pouch™ Corporate Update
In August 2012, Sernova initiated the enrollment of patients in a Phase I/II clinical trial in Canada to evaluate the safety (primary endpoint) and efficacy (secondary endpoint) of treating diabetes with transplantation of insulin-producing islets using its Cell Pouch™.
"We are continuing to enroll patients in this clinical study of Sernova's Cell Pouch™ and we expect to announce the first interim analysis of the data in the second half of 2013," said Dr. James Shapiro MD, Ph.D. FRCS (Eng.) FRCSC, principal investigator of the Cell Pouch™ study and Director of the Clinical Islet Transplantation Program at the University of Alberta.
Dr. Toleikis, President and CEO Sernova Corp added, "2013 is shaping up to be a most exciting year for Sernova. We look forward to sharing important developments while continuing our strategic plan to build Sernova into a leading technology company that will improve the health and quality of life for people with diabetes and other chronic diseases."
Sernova intends to complete the following corporate objectives in 2013:
Results of Sernova's 2013 AGM
Dr. George Adams (Chair), Jeffrey Bacha, James Parsons, Bruce Weber and Dr. Philip Toleikis, were elected as the directors of the Company to hold office until the next annual general meeting of shareholders.
Davidson & Company, Chartered Accountants, was appointed auditor of the Company until the close of the next annual general meeting of shareholders, at a remuneration to be fixed by the Directors.
About Sernova
Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is developing a platform technology based on the Cell Pouch™, Sertolin™ and therapeutic cells, for a number of chronic diseases, including insulin-dependent diabetes as a first indication and other cell therapies such as for parathyroid disease, haemophilia, and Parkinson's disease. Sernova's goals for the Cell Pouch™ for diabetes include increasing the number of patients currently treated with intraportal delivery of donor islets and to provide a safe environment for sources of unlimited insulin-secreting cells such as insulin-producing stem cells and xenogeneic cells. This vision combined with local anti-rejection protection of the cells could enable millions of patients with insulin-dependent diabetes to be treated without limitation to availability of cells.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see ). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Sernova Corp.
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
Russo Partners, LLC
Tony Russo, Ph.D.
(212) 845-4251
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.05.2013 - 04:00 Uhr
Sprache: Deutsch
News-ID 1225356
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LONDON, ONTARIO
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 112 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sernova Provides Corporate Update and Results of 2013 Annual General Meeting
"
steht unter der journalistisch-redaktionellen Verantwortung von
Sernova Corp (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
